When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Of all types of fertility treatment examined, the only one that significantly increased the risk of cancer in children was frozen embryo transfer.
Antiemetic treatment chart including drug formulations, strengths, and usual doses for nausea/vomiting.
The FDA is working in close collaboration with global regulatory partners to evaluate the controls in place and publish guidance on preventing unacceptable levels of nitrosamine in drugs.
Biosimilars Mvasi and Kanjinti are now available in the United States.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
More marked increases in incidence observed from 2006 to 2013 than from 1973 to 2006.
